scholarly journals Hepatotoxicity after high-dose intravenous methylprednisolone in multiple sclerosis patients

2017 ◽  
Vol 5 (8) ◽  
pp. 1210-1212 ◽  
Author(s):  
Milagros Hidalgo de la Cruz ◽  
Jahir Andrés Miranda Acuña ◽  
Alberto Lozano Ros ◽  
María Vega Catalina ◽  
Emilio Salinero Paniagua ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Multiple Sclerosis Patients

scholarly journals Venous Thrombosis in Multiple Sclerosis Patients after High-Dose Intravenous Methylprednisolone: The Preventive Effect of Enoxaparin

Thrombosis ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Hossein Kalanie ◽  
Ali Amini Harandi ◽  
Shapoor Alidaei ◽  
Daryoosh Heidari ◽  
Saeed Shahbeigi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Venous Thrombosis ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Relapsing Remitting ◽  
Acute Attacks ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Preventive Role

Aim. This study was designed to examine the possible role of high-dose intravenous methylprednisolone (IVMP) in the development of venous thrombosis (VT). The cerebral one anecdotally had been reported in patients with relapsing remitting multiple sclerosis (RRMS) in acute attacks and the possible preventive role of enoxaparin. Material and Methods. From a pool of 520 patients, 388 patients with definite RRMS who fulfilled entry characteristics were selected and randomly received either a 5-day course of daily 1 gr IVMP or the aforementioned plus 5 days of daily subcutaneous 40 units of enoxaparin according to a predefined protocol. Results. Mean age, gender ratio, mean relapse rate, and EDSS were similar in both groups of patients (P > 0.05). Finally, 366 patients remained in the study. Of 188 patients treated with IVMP with 855 relapses, 5 developed VT (0.37% per patient per year and 0.58% per each course of IVMP) within 3 to 15 days of starting therapy. None of the 178 patients who experienced 809 relapses who received IVMP plus enoxaparin developed such complications. Conclusion. The study implies that high-dose IVMP in MS exacerbation may increase the risk of VT and prophylactic anticoagulant treatment in this setting is warranted.

A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone

Neurology ◽  
1992 ◽  
Vol 42 (1) ◽  
pp. 63-63 ◽  
Author(s):  
F. Barkhof ◽  
S. T.F.M. Frequin ◽  
O. R. Hommes ◽  
K. Lamers ◽  
W.J.A. van Geel ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Gadolinium Dtpa ◽  
Multiple Sclerosis Patients ◽  
Relapsing Multiple Sclerosis

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

2002 ◽  
Vol 8 (5) ◽  
pp. 415-419 ◽  
Author(s):  
E LJ Hoogervorst ◽  
C H Polman ◽  
F Barkhof
Keyword(s):  
Multiple Sclerosis ◽  
Brain Volume ◽  
Disease Onset ◽  
Cerebral Atrophy ◽  
Oral Prednisolone ◽  
Prolonged Treatment ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Intravenous Steroids ◽  
Multiple Sclerosis Patients

Objective: Multiple sclerosis (MS) patients develop varying degrees of cerebral atrophy, which may already begin at disease onset. The purpose of this study is to examine the effect of steroid treatment on cerebral volume in MS patients. Methods: Thirty-five MS patients participating in a clinical trial of oral interferon beta, which included monthly MRI, were included in this study. They suffered from an acute relapse and were treated with intravenous methylprednisolone (IV-MP); 13 of the patients were treated with oral prednisolone tapering after IV-MP. The last MRI scan before and the first (and second for oral tapering patients) scan after IV-MP treatment were used for measuring parenchymal fraction (PF) and ventricular fraction (VF). Changes in PF and VF were analysed using Student’s t test. Results: For the total population no significant changes in PF or VF were found. However, the subgroup of patients receiving oral tapering after IV-MP showed changes, compatible with atrophy in both PF and VF, that were significant immediately after IV-MP treatment and still persisted (though not statistically significant anymore) after a mean interval of 30 days. The magnitude of these changes was about the same as the annual change in cerebral volume as reported in natural history studies. Conclusion: Our data indicate that short courses of intravenous steroids (restricted to three or five days) have no major impact, whereas prolonged treatment with oral tapering does significantly affect brain volume. These findings are important for longitudinal studies and clinical trials in which brain volume is used as an outcome measure.

Suppressive effect of glucocorticoids on TNF-α production is associated with their clinical effect in multiple sclerosis

2010 ◽  
Vol 16 (4) ◽  
pp. 500-502 ◽  
Author(s):  
Lisa ML van Winsen ◽  
Chris H Polman ◽  
Christine D Dijkstra ◽  
Fred JH Tilders ◽  
Bernard MJ Uitdehaag
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Effect ◽  
Suppressive Effect ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Tnf Α ◽  
Before And After ◽  
Effect Of Treatment ◽  
Multiple Sclerosis Patients

A reduced sensitivity to glucocorticoids can affect the clinical effect of treatment with high-dose intravenous methylprednisolone in multiple sclerosis. We prospectively studied 27 multiple sclerosis patients who were treated with intravenous methylprednisolone. Before and after treatment in vitro stimulated TNF-α production in blood cells and the effect of in vitro administered glucocorticoids were determined as a measure of glucocorticoid sensitivity. The suppression of TNF-α production after intravenous methylprednisolone, and the in vitro suppressive effect of glucocorticoids prior to treatment was related to subsequent clinical improvement after intravenous methylprednisolone. The results suggest the existence of a partial glucocorticoid resistance, in a subgroup of multiple sclerosis patients, which may have implications for treatment efficacy.

Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone

1993 ◽  
Vol 240 (5) ◽  
pp. 305-308 ◽  
Author(s):  
Stephan T. F. M. Frequin ◽  
Ron A. Wevers ◽  
Majorie Braam ◽  
Frederik Barkhof ◽  
Otto R. Hommes
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Vitamin B12 ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Multiple Sclerosis Patients

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations

Neurology ◽  
1986 ◽  
Vol 36 (2) ◽  
pp. 238-238 ◽  
Author(s):  
L. Durelli ◽  
D. Cocito ◽  
A. Riccio ◽  
C. Barile ◽  
B. Bergamasco ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Intravenous Methylprednisolone

scholarly journals High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

2019 ◽  
Vol 26 (14) ◽  
pp. 1898-1906 ◽  
Author(s):  
Laura Couloume ◽  
Laetitia Barbin ◽  
Emmanuelle Leray ◽  
Sandrine Wiertlewski ◽  
Emmanuelle Le Page ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Practice ◽  
Prospective Study ◽  
Outcome Measures ◽  
Progressive Multiple Sclerosis ◽  
Routine Clinical Practice ◽  
High Dose ◽  
Disability Progression ◽  
Edss Score ◽  
Multiple Sclerosis Patients

Background: A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis. Objective: To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months. Methods: Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months. Results: A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event. Conclusion: In this study, high-dose biotin did not seem to be associated with a clear improvement in disability.

Sign in / Sign up

Export Citation Format

Share Document